TriSalus Life Sciences (TLSI) Enterprise Value (2020 - 2026)

TriSalus Life Sciences' Enterprise Value history runs 7 years deep, the most recent figure standing at -$56.6 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 335.02% year-over-year to -$56.6 million in Q1 2026; TTM through Mar 2026 was -$56.6 million, a 335.02% decrease from a year earlier, with the FY2025 full-year figure at -$20.4 million, down 139.75% from the prior year.
• Enterprise Value declined to -$56.6 million in Q1 2026 per TLSI's latest filing, from -$20.4 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$69182.0 in Q2 2022 and bottomed at -$56.6 million in Q1 2026.
• The 5-year median for Enterprise Value is -$11.8 million (2023), against an average of -$14.8 million.
• Across the five-year window, Enterprise Value soared 89.24% in 2022 and tumbled 15750.93% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$9.4 million in 2022, then fell by 25.1% to -$11.8 million in 2023, then advanced by 27.61% to -$8.5 million in 2024, then slumped by 139.75% to -$20.4 million in 2025, then plunged by 176.69% to -$56.6 million in 2026.
• Per Business Quant, the three latest TLSI Enterprise Value figures stand at -$56.6 million (Q1 2026), -$20.4 million (Q4 2025), and -$22.7 million (Q3 2025).